PRN — Profound Medical Income Statement
0.000.00%
Last trade - 00:00
- CA$274.58m
- CA$249.72m
- $7.20m
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.17 | 7.3 | 6.87 | 6.68 | 7.2 |
Cost of Revenue | |||||
Gross Profit | 2.39 | 3.47 | 2.95 | 3.02 | 4.38 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 19.1 | 26.2 | 37.2 | 38.8 | 35.8 |
Operating Profit | -14.9 | -18.9 | -30.3 | -32.1 | -28.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -15.1 | -21.6 | -30.6 | -28.4 | -28.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -15.2 | -21.6 | -30.7 | -28.7 | -28.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -15.2 | -21.6 | -30.7 | -28.7 | -28.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -15.2 | -21.6 | -30.7 | -28.7 | -28.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.37 | -1.26 | -1.5 | -1.3 | -1.35 |